微粒化非诺贝特对原发性高脂血症病人血脂和血液流变性的影响  

Effects of micronised fenofibrate on serum lipid level and hemorheologic changes in patients with primary hyperlipidemia

作　　者：黎明江[1] 胡成林[1] 王晋明[1] 张庆华[1] 许家琍[1] 

机构地区：[1]湖北医科大学附属第一医院心内科

出　　处：《中国新药与临床杂志》1999年第2期89-91,共3页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的：观察微粒化非诺贝特的降血脂疗效及是否有改善血液流变性的作用。方法：６７例原发性高脂血症病人（男性５１例，女性１６例；年龄５４ａ±ｓ１１ａ）给微粒化非诺贝特２００ｍｇ，ｐｏ，ｑｎ，疗程８ｗｋ。结果：治疗８ｗｋ后血清三酰甘油、总胆固醇、低密度脂蛋白胆固醇和载脂蛋白Ｂ１００显著低于治疗前水平（Ｐ＜０．０１或Ｐ＜０．０５），高密度脂蛋白胆固醇与载脂蛋白ＡＩ升高，（Ｐ＜０．０５）；另外血浆粘度、凝血因子Ｉ、血小板粘附率和血细胞比容较治疗前明显下降（Ｐ＜０．０１或Ｐ＜０．０５）。结论：微粒化非诺贝特能有效降低高血脂，同时明显改善了病人的高粘血症。AIM: To study the effects of micronised fenofibrate on serum lipid level and hemorheologic changes in patients with primary hyperlipidemia. METHODS: Sixty_seven patients (M 51, F 16; age 54 a±s 11 a) with hyperlipidemia received micronised fenofibrate 200 mg (200 mg/cap), po, qn×8 wk. RESULTS: After 8 wk, total cholesterol, triglyceride, low density lipoprotein cholesterol, and apolipoprotein B 100 levels were decreased (P<0.01 or P<0.05), high density lipoprotein cholesterol and apolipoprotein AI level was increased (P<0.05); plasma viscosity, fibrinogen, platelet adhesion rate , and hematocrit were decreased ( P < 0.01 or P<0.05). CONCLUSION: Micronised fenofibrate is beneficial on adjusting lipid level and blood viscosity.

关 键 词：非诺贝特 高脂血症 血液流变学 治疗 

分 类 号：R589.205[医药卫生—内分泌]